IOL glistenings

Intercontinental collaboration is key to unlocking ROP in our lifetime

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration